Jantunen, E., Kuittinen, T., & Nousiainen, T. (2002). A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. Leukemia and Lymphoma, 43, 1961–1965.
The study was conducted between November 1998 and February 2000.
This was a pilot, feasibility study.
The National Cancer Institute (NCI) Common Toxicity Criteria for Oral Mucositis was used to assess oral mucositis daily.
Most of the patients (9 out of 10) received the full dose of amifostine. One patient received only 780 mg/m2 because of recurrent hypotension. Significant nausea, as well as hypotension and vomiting, occurred.
Amifostine did not show a benefit for gastrointestinal toxicity or mucositis of more than grade 2.